Training and Career Development: Translational Drug Therapy – T17
The special emphasis panel reviews training and career development applications in translational drug therapy including applications related to drug discovery; mechanism of action of cancer therapeutic agents in both in vitro and in vivo model systems; development and evaluation of experimental therapies of neoplastic diseases; and development or optimization of treatment modalities.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Discovery and characterization of novel anti-cancer agents including small molecule inhibitors, natural products, peptides/proteins/peptidomimetics, repurposed drugs, immunomodulators, and combination regimens
- Optimization and preclinical studies of anti-cancer agents, including medicinal chemistry, hit-to-lead optimization; combination regimens, and early and late-stage toxicity and PK/PD studies in cellular and animal models.
- Identification and validation of combination therapies to maximize the efficacy of cancer treatments including rational combinations of conventional and targeted therapies with novel agents.
- Evaluation of gene and drug-delivery strategies (nonimmunological), including reformulation/combination of existing drugs or formulation development of evidence based new drugs
- Mechanism of action of established or repurposed cancer therapeutics (previously tested in model organisms and/or humans), spanning small molecule, peptide, protein, cellular, and genetic experimental therapeutics.
- Mechanisms of resistance to established cancer therapeutics and strategies to circumvent intrinsic and extrinsic resistance mechanisms, including genetic and chemical screens.
